Page 106 - 南京医科大学自然版
P. 106
第44卷第5期
·694 · 南 京 医 科 大 学 学 报 2024年5月
提供了与患者肿瘤高度相似的研究工具,在GBM化 Regorafenib compared with lomustine in patients with re⁃
疗耐药研究中起着关键作用。一方面,GBO模型为 lapsed glioblastoma(REGOMA):a multicentre,open⁃la⁃
个体化治疗提供了高通量的药物筛选和验证平台, bel,randomised,controlled,phase 2 trial[J]. Lancet On⁃
用于精准确定个体化辅助治疗药物,提高复发患者的 col,2019,20(1):110-119
[6] REARDON D A,BRANDES A A,OMURO A,et al.
生存率 [77-78] ;另一方面,GBO模型能够保留患者肿瘤
Effect of nivolumab vs bevacizumab in patients with re⁃
中的相关生物标志物,预测患者对治疗的反应 [79-80] 。
current glioblastoma:the checkmate 143 phase 3 random⁃
例如,研究人员通过 GBO 进行前瞻性药物筛选,预 ized clinical trial[J]. JAMA Oncol,2020,6(7):1003-
测患者对厄洛替尼、维罗非尼和依维莫司的响应 1010
性,依据预测结果选择使用依维莫司并在患者中取 [7] TSIEN C I,PUGH S L,DICKER A P,et al. NRG oncolo⁃
得了较好的疗效 。 gy/RTOG1205:a randomized phase Ⅱ trial of concurrent
[81]
bevacizumab and reirradiation versus bevacizumab alone
4 未来展望 as treatment for recurrent glioblastoma[J]. J Clin Oncol,
2023,41(6):1285-1295
尽管 GBM 的治疗方法在过去几年中取得了一
[8] LIM M,WELLER M,IDBAIH A,et al. Phase Ⅲ trial of
定的进展,但患者 5 年生存率仍然很低,并且复发
chemoradiotherapy with temozolomide plus nivolumab or
GBM 患者通常比初发患者表现出更加复杂的分子
placebo for newly diagnosed glioblastoma with methylated
特征和通路异常,使得治疗变得尤为困难。越来越 MGMT promoter[J]. Neuro ⁃ oncology,2022,24(11):
多的研究证明 TMZ 耐药是由多个分子事件共同作 1935-1949
用的结果。这些事件在不同层面发挥作用,导致单 [9] OMURO A,BRANDES A A,CARPENTIER A F,et al.
一疗法很难为患者带来显著益处。因此,多模式治 Radiotherapy combined with nivolumab or temozolomide
疗方法,即结合多种不同治疗手段开发的新型治疗 for newly diagnosed glioblastoma with unmethylated
策略正在 GBM 治疗中显示出潜力,包括靶向疗法、 MGMT promoter:an international randomized phase Ⅲ
trial[J]. Neuro Oncol,2023,25(1):123-134
免疫治疗等。随着科学技术的进步和对 GBM 生物
[10]TOMAR M S,KUMAR A,SRIVASTAVA C,et al. Eluci⁃
学的深入了解,未来的治疗策略将更加多元化,更
dating the mechanisms of temozolomide resistance in glio⁃
加精准地针对肿瘤的异质性和复杂性进行个体化
mas and the strategies to overcome the resistance[J]. Bio⁃
治疗,延缓甚至阻断 TMZ耐药,提高治疗效果,延长 chim Biophys Acta Rev Cancer,2021,1876(2):188616
患者的生存期,为患者带来新的希望。 [11]OLDRINI B,VAQUERO ⁃ SIGUERO N,MU Q H,et al.
MGMT genomic rearrangements contribute to chemothera⁃
[参考文献]
py resistance in gliomas[J]. Nat Commun,2020,11(1):
[1] WELLER M,VAN DEN BENT M,PREUSSER M,et al.
3883
EANO guidelines on the diagnosis and treatment of dif⁃
[12]WICK W,PLATTEN M,MEISNER C,et al. Temozolo⁃
fuse gliomas of adulthood[J]. Nat Rev Clin Oncol,2021,
mide chemotherapy alone versus radiotherapy alone for
18(3):170-186
malignant astrocytoma in the elderly:the NOA ⁃ 08 ran⁃
[2] STUPP R,MASON W P,VAN DEN BENT M J,et al. Ra⁃ domised,phase 3 trial[J]. Lancet Oncol,2012,13(7):
diotherapy plus concomitant and adjuvant temozolomide
707-715
for glioblastoma[J]. N Engl J Med,2005,352(10):987-
[13]BRANDES A A ,FRANCESCHI E ,TOSONI A ,et al.
996
O(6)⁃methylguanine DNA⁃methyltransferase methylation
[3] MEDICAL RESEARCH COUNCIL BRAIN TUMOR
status can change between first surgery for newly ding⁃
WORKING PARTY. Randomized trial of procarbazine,
nosed glioblastoma and second sugery for recurrence:clini⁃
lomustine,and vincristine in the adjuvant treatment of high⁃
cal implications[J]. Neuro Oncol,2010,12(3):283-288
grade astrocytoma:a medical research council trial[J]. J
[14]GAN T,WANG Y,XIE M Y,et al. MEX3A impairs DNA
Clin Oncol,2001,19(2):509-518
mismatch repair signaling and mediates acquired temo⁃
[4] KIM S H,YOO H,CHANG J H,et al. Procarbazine and zolomide resistance in glioblastoma[J]. Cancer Res,
CCNU chemotherapy for recurrent glioblastoma with
2022,82(22):4234-4246
MGMT promoter methylation[J]. J Korean Med Sci, [15]FELSBERG J,THON N,EIGENBROD S,et al. Promoter
2018,33(24):167 methylation and expression of MGMT and the DNA mis⁃
[5] LOMBARDI G,DE SALVO G L,BRANDES A A,et al. match repair genes MLH1,MSH2,MSH6 and PMS2 in